IN2015DN03133A - - Google Patents

Info

Publication number
IN2015DN03133A
IN2015DN03133A IN3133DEN2015A IN2015DN03133A IN 2015DN03133 A IN2015DN03133 A IN 2015DN03133A IN 3133DEN2015 A IN3133DEN2015 A IN 3133DEN2015A IN 2015DN03133 A IN2015DN03133 A IN 2015DN03133A
Authority
IN
India
Prior art keywords
compounds
pyridazinone
disclosure
thyroid hormone
allow
Prior art date
Application number
Other languages
English (en)
Inventor
D Keith Hester
Robert J Duguid
Martha Kelly
Anna Chasnoff
Gang Dong
Edwin L Crow
Rebecca Taub
Charles H Reynolds
Duk Soon Choi
Lianhe Shu
Ping Wang
Original Assignee
Madrigal Pharmaceuticals Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc, Hoffmann La Roche filed Critical Madrigal Pharmaceuticals Inc
Publication of IN2015DN03133A publication Critical patent/IN2015DN03133A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IN3133DEN2015 2012-09-17 2013-09-17 IN2015DN03133A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702137P 2012-09-17 2012-09-17
US201361790432P 2013-03-15 2013-03-15
PCT/US2013/060177 WO2014043706A1 (fr) 2012-09-17 2013-09-17 Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes

Publications (1)

Publication Number Publication Date
IN2015DN03133A true IN2015DN03133A (fr) 2015-10-02

Family

ID=50278769

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3133DEN2015 IN2015DN03133A (fr) 2012-09-17 2013-09-17

Country Status (31)

Country Link
US (8) US9266861B2 (fr)
EP (5) EP3689853B1 (fr)
JP (8) JP6616688B2 (fr)
KR (4) KR102363776B1 (fr)
CN (2) CN105008335B (fr)
AR (1) AR092872A1 (fr)
AU (1) AU2013315017C1 (fr)
BR (2) BR122021024202B1 (fr)
CA (3) CA2884481C (fr)
DK (3) DK4406594T3 (fr)
ES (3) ES2795450T3 (fr)
FI (2) FI4406594T3 (fr)
FR (1) FR26C1009I1 (fr)
HR (1) HRP20251398T1 (fr)
IL (7) IL314360B2 (fr)
IN (1) IN2015DN03133A (fr)
LT (2) LT4406594T (fr)
MX (2) MX364661B (fr)
MY (1) MY170520A (fr)
NL (1) NL301369I2 (fr)
NO (1) NO2026010I1 (fr)
NZ (2) NZ739645A (fr)
PL (1) PL4406594T3 (fr)
PT (1) PT4406594T (fr)
RS (1) RS67728B1 (fr)
RU (2) RU2668960C2 (fr)
SG (3) SG10202006058QA (fr)
SI (1) SI4406594T1 (fr)
TW (4) TWI681957B (fr)
WO (1) WO2014043706A1 (fr)
ZA (1) ZA201501795B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
WO2018075650A1 (fr) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Méthodes de traitement de troubles hépatiques ou de troubles lipidiques avec un agoniste thr-bêta
JP7156722B2 (ja) * 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CA3113373A1 (fr) * 2018-10-12 2020-04-16 InventisBio Co., Ltd. Agonistes du recepteur des hormones thyroidiennes
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN113474335B (zh) * 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2020228577A1 (fr) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
WO2020239076A1 (fr) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 DÉRIVÉS DE PYRIDAZINONE CONSTITUANT DES AGONISTES DU RÉCEPTEUR DE LA THYROXINE DE TYPE β ET LEUR UTILISATION
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021043185A1 (fr) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
WO2021050945A1 (fr) 2019-09-12 2021-03-18 Terns, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
WO2021063367A1 (fr) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
WO2021104288A1 (fr) 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
WO2022041026A1 (fr) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Composés de pyridazinone
WO2022052822A1 (fr) * 2020-09-10 2022-03-17 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
EP4204419A1 (fr) 2020-10-19 2023-07-05 Teva Pharmaceuticals International GmbH Formes solides de resmetirom
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN118251221A (zh) 2021-09-27 2024-06-25 马德里加尔制药公司 用于减少肝脏体积的瑞司美替罗
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
EP4568664B1 (fr) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combinaison comprenant un agoniste thr-beta et un agoniste glp-1r pour son utilisation dans le traitement de l'obésité
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
WO2024263714A1 (fr) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARQUEURS POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES AVEC DES AGONISTES THR-β ET UTILISATIONS ASSOCIÉES
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
CN117263870B (zh) * 2023-09-21 2026-02-06 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
WO2025083699A2 (fr) 2023-10-16 2025-04-24 Cipla Limited Polymorphes de resmétirom et procédé associé
WO2025125576A2 (fr) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
WO2025133348A1 (fr) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
EP4686757A1 (fr) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibiteurs d expression et/ou de fonction
WO2025164161A1 (fr) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 Solvate de cannabidiol et procédé de purification de cannabidiol
WO2025171032A1 (fr) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Méthodes de traitement d'une stéatose hépatique
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (fr) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Procédé de préparation d'un dérivé de pyridazinone
CN119019375A (zh) * 2024-08-14 2024-11-26 奥锐特药业(天津)有限公司 一种瑞司美替罗新晶型及其制备方法
WO2026067708A1 (fr) * 2024-09-30 2026-04-02 齐鲁制药有限公司 Formes cristallines de resmétirom, son procédé de préparation et son utilisation
WO2026074443A1 (fr) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Formes solides de resmétirom
CN119306670A (zh) * 2024-10-12 2025-01-14 北京海美桐医药科技有限公司 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
MXPA05008080A (es) * 2003-01-28 2006-02-08 Octoplus Technologies B V Inhibidores peptidicos de toxinas derivadas de la ll-37.
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US20080152700A1 (en) * 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
CA2589106C (fr) 2004-11-02 2015-07-21 Northwestern University Composes pyridazine, compositions et procedes associes et leur utilisation dans le traitement de maladies inflammatoires
DK1919878T3 (da) * 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
HRP20100611T1 (hr) * 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AR092872A1 (es) * 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
CN106132969A (zh) 2014-02-14 2016-11-16 森普拉制药公司 用于治疗糖尿病和肝病的组合物和方法
WO2018075650A1 (fr) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Méthodes de traitement de troubles hépatiques ou de troubles lipidiques avec un agoniste thr-bêta
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
AR115666A1 (es) 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CA3113373A1 (fr) 2018-10-12 2020-04-16 InventisBio Co., Ltd. Agonistes du recepteur des hormones thyroidiennes
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
IL320269A (en) 2025-06-01
EP2895466B1 (fr) 2020-03-25
EP4406594A2 (fr) 2024-07-31
JP2019048856A (ja) 2019-03-28
EP4023641A3 (fr) 2022-09-14
CA3090070C (fr) 2023-01-24
RU2015114327A (ru) 2016-11-10
LT4406594T (lt) 2025-12-29
NZ739645A (en) 2019-11-29
CN108101851A (zh) 2018-06-01
EP4023641B1 (fr) 2024-05-01
NO2026010I1 (no) 2026-03-03
RU2668960C2 (ru) 2018-10-05
IL275393B (en) 2022-01-01
US20160243126A1 (en) 2016-08-25
FIC20265007I1 (fi) 2026-03-03
IL275393A (en) 2020-07-30
JP6532931B2 (ja) 2019-06-19
NZ705827A (en) 2018-07-27
EP3689853B1 (fr) 2021-11-24
AU2013315017A1 (en) 2015-04-02
DK3689853T3 (da) 2022-03-07
ES2795450T3 (es) 2020-11-23
IL314360B1 (en) 2025-05-01
US20240122936A1 (en) 2024-04-18
US20240148742A1 (en) 2024-05-09
AR092872A1 (es) 2015-05-06
DK2895466T3 (da) 2020-06-08
JP2020015739A (ja) 2020-01-30
US9266861B2 (en) 2016-02-23
TWI652260B (zh) 2019-03-01
ZA201501795B (en) 2021-10-27
JP6616688B2 (ja) 2019-12-04
JP6899413B2 (ja) 2021-07-07
PT4406594T (pt) 2025-11-28
KR102138750B1 (ko) 2020-07-29
NL301369I2 (nl) 2026-03-30
US10894050B2 (en) 2021-01-19
IL259610A (en) 2018-07-31
IL288133A (en) 2022-01-01
KR20150056630A (ko) 2015-05-26
JP2025179154A (ja) 2025-12-09
JP2020109090A (ja) 2020-07-16
EP3689853A1 (fr) 2020-08-05
JP7436542B2 (ja) 2024-02-21
EP2895466A4 (fr) 2016-08-10
EP4691557A2 (fr) 2026-02-11
US9968612B2 (en) 2018-05-15
SG10201705984XA (en) 2017-08-30
IL288133B1 (en) 2024-08-01
RS67728B1 (sr) 2026-03-31
MX2018014924A (es) 2020-09-02
US20210161904A1 (en) 2021-06-03
US11986481B2 (en) 2024-05-21
KR20180131647A (ko) 2018-12-10
WO2014043706A1 (fr) 2014-03-20
EP2895466A1 (fr) 2015-07-22
BR112015005891A2 (pt) 2017-08-08
IL259610B (en) 2020-06-30
AU2013315017C1 (en) 2017-11-23
TWI755628B (zh) 2022-02-21
EP4691557A3 (fr) 2026-03-18
MX2015003418A (es) 2016-04-04
SG10202006058QA (en) 2020-08-28
TW201946917A (zh) 2019-12-16
CN105008335B (zh) 2018-12-21
HK1212682A1 (en) 2016-06-17
EP4406594A3 (fr) 2024-11-06
IL237628B (en) 2019-07-31
US20150203473A1 (en) 2015-07-23
JP6765408B2 (ja) 2020-10-07
EP4406594B1 (fr) 2025-09-10
US10376517B2 (en) 2019-08-13
KR102363776B1 (ko) 2022-02-15
EP4023641A2 (fr) 2022-07-06
IL265030B (en) 2020-07-30
KR20210083381A (ko) 2021-07-06
KR101966490B1 (ko) 2019-08-14
MY170520A (en) 2019-08-08
TWI804870B (zh) 2023-06-11
WO2014043706A8 (fr) 2017-10-19
FI4406594T3 (fi) 2025-11-26
RU2018128393A3 (fr) 2019-04-16
US20190381053A1 (en) 2019-12-19
PL4406594T3 (pl) 2026-03-30
IL314360A (en) 2024-09-01
TW202134217A (zh) 2021-09-16
CA3090070A1 (fr) 2014-03-20
US11564926B2 (en) 2023-01-31
SG11201501907YA (en) 2015-04-29
JP2024056793A (ja) 2024-04-23
HRP20251398T1 (hr) 2026-03-13
RU2018128393A (ru) 2019-03-14
JP7038745B2 (ja) 2022-03-18
TW201425300A (zh) 2014-07-01
JP2018080188A (ja) 2018-05-24
US20230210856A1 (en) 2023-07-06
ES2907926T3 (es) 2022-04-27
JP2015535817A (ja) 2015-12-17
LTPA2026507I1 (fr) 2026-03-10
TWI681957B (zh) 2020-01-11
IL314360B2 (en) 2025-09-01
IL237628A0 (en) 2015-04-30
MX395148B (es) 2025-03-24
AU2013315017B2 (en) 2017-07-27
FR26C1009I1 (fr) 2026-04-17
IL288133B2 (en) 2024-12-01
DK4406594T3 (da) 2025-11-03
CA2884481C (fr) 2021-04-27
SI4406594T1 (sl) 2026-03-31
JP2022078218A (ja) 2022-05-24
BR122021024202B1 (pt) 2022-05-17
CA3111317A1 (fr) 2014-03-20
ES3053122T3 (en) 2026-01-19
CA3111317C (fr) 2023-08-29
CA2884481A1 (fr) 2014-03-20
MX364661B (es) 2019-05-03
US20180228807A1 (en) 2018-08-16
TW201906835A (zh) 2019-02-16
KR20200023528A (ko) 2020-03-04
CN105008335A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
IN2015DN03133A (fr)
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
GEP20186826B (en) Intermediate product for treprostinil synthesis and methods for preparation thereof
MY178759A (en) Method for preparing trichlorosilane
PH12012501438A1 (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
IN2014MN00976A (fr)
IN2015MN00013A (fr)
MX2010005015A (es) Metodos para preparar capecitabina y un compuesto de carbonato trialquilo rico en beta-anomero.
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
EP3760637A3 (fr) Formes solides stables du régadénoson
BR112012031086A2 (pt) intermediários de agomelatina e método de preparação dos mesmos
PH12014502495A1 (en) Method for producing refined glycerin alkyl ether
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12013500609A1 (en) Novel method of preparing benzoimidazole derivatives
WO2012115402A3 (fr) Forme cristalline du docétaxel et procédé de préparation associé
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
IN2014DN03245A (fr)
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
MX2014001009A (es) Metodos para aislar acidos 4-cloro-2-fluoro-3-fenilboronicos sustituidos.
PH12015501840A1 (en) Production method of pyridazinone compounds
GB201103455D0 (en) Radiofluorination method
IN2012DE00267A (fr)
IN2013MU03467A (fr)
IN2011CH03419A (fr)